161 related articles for article (PubMed ID: 29167469)
1. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
Paolucci S; Premoli M; Novati S; Gulminetti R; Maserati R; Barbarini G; Sacchi P; Piralla A; Sassera D; De Marco L; Girello A; Mondelli MU; Baldanti F
Sci Rep; 2017 Nov; 7(1):16017. PubMed ID: 29167469
[TBL] [Abstract][Full Text] [Related]
2. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
[TBL] [Abstract][Full Text] [Related]
3. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
[TBL] [Abstract][Full Text] [Related]
4. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
[TBL] [Abstract][Full Text] [Related]
5. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
[TBL] [Abstract][Full Text] [Related]
6. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
[TBL] [Abstract][Full Text] [Related]
8. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.
Liu Z; Mao X; Yu K; Suo C; Jin L; Zhang T; Chen X
J Viral Hepat; 2020 Jun; 27(6):585-592. PubMed ID: 32049405
[TBL] [Abstract][Full Text] [Related]
10. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
Dietz J; Kalinina OV; Vermehren J; Peiffer KH; Matschenz K; Buggisch P; Niederau C; Schattenberg JM; Müllhaupt B; Yerly S; Ringelhan M; Schmid RM; Antoni C; Müller T; Schulze Zur Wiesch J; Piecha F; Moradpour D; Deterding K; Wedemeyer H; Moreno C; Berg T; Berg CP; Zeuzem S; Welsch C; Sarrazin C;
J Viral Hepat; 2020 Oct; 27(10):974-986. PubMed ID: 32396998
[TBL] [Abstract][Full Text] [Related]
11. Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.
Hong CM; Lin YY; Liu CJ; Lai YY; Yeh SH; Yang HC; Kao JH; Hsu SJ; Huang YH; Yang SS; Kuo HT; Cheng PN; Yu ML; Chen PJ
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835100
[TBL] [Abstract][Full Text] [Related]
12. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.
Sayan M; Yıldırım FS; Akhan S; Yıldırım AA; Şirin G; Cabalak M; Demir M; Can S; Ersöz G; Altıntaş E; Ensaroğlu F; Akbulut A; Şener A; Deveci A
Int J Infect Dis; 2020 Jun; 95():84-89. PubMed ID: 32302766
[TBL] [Abstract][Full Text] [Related]
13. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
14. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
15. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
16. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
Mo H; Hedskog C; Lawitz E; Brainard DM; Yang J; Delaney W; Worth A; Miller MD
Antiviral Res; 2017 Apr; 140():151-157. PubMed ID: 28132867
[TBL] [Abstract][Full Text] [Related]
17. Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.
Mushtaq S; Hashmi AH; Khan A; Asad Raza Kazmi SM; Manzoor S
Front Pharmacol; 2022; 13():894460. PubMed ID: 35571102
[No Abstract] [Full Text] [Related]
18. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review.
Onorato L; Pisaturo M; Starace M; Minichini C; Di Fraia A; Astorri R; Coppola N
Viruses; 2021 Mar; 13(3):. PubMed ID: 33800289
[TBL] [Abstract][Full Text] [Related]
19. Resistance to DAAs: When to Look and When It Matters.
Wyles DL
Curr HIV/AIDS Rep; 2017 Dec; 14(6):229-237. PubMed ID: 29116550
[TBL] [Abstract][Full Text] [Related]
20. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.
Chen Q; Perales C; Soria ME; García-Cehic D; Gregori J; Rodríguez-Frías F; Buti M; Crespo J; Calleja JL; Tabernero D; Vila M; Lázaro F; Rando-Segura A; Nieto-Aponte L; Llorens-Revull M; Cortese MF; Fernandez-Alonso I; Castellote J; Niubó J; Imaz A; Xiol X; Castells L; Riveiro-Barciela M; Llaneras J; Navarro J; Vargas-Blasco V; Augustin S; Conde I; Rubín Á; Prieto M; Torras X; Margall N; Forns X; Mariño Z; Lens S; Bonacci M; Pérez-Del-Pulgar S; Londoño MC; García-Buey ML; Sanz-Cameno P; Morillas R; Martró E; Saludes V; Masnou-Ridaura H; Salmerón J; Quíles R; Carrión JA; Forné M; Rosinach M; Fernández I; García-Samaniego J; Madejón A; Castillo-Grau P; López-Núñez C; Ferri MJ; Durández R; Sáez-Royuela F; Diago M; Gimeno C; Medina R; Buenestado J; Bernet A; Turnes J; Trigo-Daporta M; Hernández-Guerra M; Delgado-Blanco M; Cañizares A; Arenas JI; Gomez-Alonso MJ; Rodríguez M; Deig E; Olivé G; Río OD; Cabezas J; Quiñones I; Roget M; Montoliu S; García-Costa J; Force L; Blanch S; Miralbés M; López-de-Goicoechea MJ; García-Flores A; Saumoy M; Casanovas T; Baliellas C; Gilabert P; Martin-Cardona A; Roca R; Barenys M; Villaverde J; Salord S; Camps B; Silvan di Yacovo M; Ocaña I; Sauleda S; Bes M; Carbonell J; Vargas-Accarino E; Ruzo SP; Guerrero-Murillo M; Von Massow G; Costafreda MI; López RM; González-Moreno L; Real Y; Acero-Fernández D; Viroles S; Pamplona X; Cairó M; Ocete MD; Macías-Sánchez JF; Estébanez A; Quer JC; Mena-de-Cea Á; Otero A; Castro-Iglesias Á; Suárez F; Vázquez Á; Vieito D; López-Calvo S; Vázquez-Rodríguez P; Martínez-Cerezo FJ; Rodríguez R; Macenlle R; Cachero A; Mereish G; Mora-Moruny C; Fábregas S; Sacristán B; Albillos A; Sánchez-Ruano JJ; Baluja-Pino R; Fernández-Fernández J; González-Portela C; García-Martin C; Sánchez-Antolín G; Andrade RJ; Simón MA; Pascasio JM; Romero-Gómez M; Antonio Del-Campo J; Domingo E; Esteban R; Esteban JI; Quer J
Antiviral Res; 2020 Feb; 174():104694. PubMed ID: 31857134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
